ticker,end_date,stage,price,drug,date_text
AMAG,02/02/2018,PDUFA,14.30,Feraheme,
AVEO,02/08/2018,Phase 1/2,2.99,Tivozanib + Opdivo,"February 8-10, 2018;"
FOLD,02/08/2018,Phase 1/2,16.40,ATB200,
JNJ,02/08/2018,PDUFA priority review,137.68,Apalutamide,
JNJ,02/08/2018,PDUFA,137.68,ZYTIGA (abiraterone acetate) - LATITUDE,"February 8/9, 2018;"
CBIO,02/09/2018,Phase 1/2,25.27,CB 2679d/ ISU304,
JNJ,02/09/2018,Phase 2,137.68,Erdafitinib,"February 9, 2018;"
TCON,02/10/2018,Phase 2,2.80,DE-122 and Lucentis - AVANTE,
GILD,02/12/2018,PDUFA priority review,81.73,Bictegravir/F/TAF,
VRX,02/13/2018,PDUFA,18.00,Plenvu (NER1006),
AMAG,02/14/2018,PDUFA,14.30,Makena - auto injector,
ATRS,02/14/2018,PDUFA,2.00,Makena - auto injector,
CELG,02/14/2018,Phase 2,99.80,OTEZLA,"February 14-17, 2018;"
PCRX,02/14/2018,PDUFA,38.50,EXPAREL,Adcom 2/14/18; PDUFA 4/6/18;
KURA,02/15/2018,Phase 2,19.80,Tipifarnib,"February 15-17, 2018;"
APRI,02/17/2018,PDUFA,2.22,Vitaros,
IMNP,02/17/2018,Phase 2,0.47,Bertilimumab,
KMPH,02/23/2018,PDUFA,6.35,KP201/APAP,
AIMT,02/28/2018,Phase 3,36.18,AR101 PALISADE,February 2018;
AST,02/28/2018,Phase 1/2,2.00,AST-OPC1 SCiSTAR,February 2018;
CRMD,02/28/2018,Phase 3,0.46,Neutrolin - LOCK-IT 100,Early 2018;
HTBX,02/28/2018,Phase 2,3.23,HS-110 and nivolumab (Opdivo),
KDMN,02/28/2018,Phase 2,5.14,KD025,February 2018;
MDGL,02/28/2018,Phase 2,147.99,MGL-3196,Early 2018;
MRNS,02/28/2018,Phase 2,6.92,Ganaxolone,Early 2018;
NVAX,02/28/2018,Phase 1/2,2.00,NanoFlu vaccine,Feb 2018;
RXII,02/28/2018,Phase 1/2,3.94,RXI-109-1501,Early 2018;
SRNE,02/28/2018,PDUFA,7.65,ZTlido (lidocaine patch 1.8%),
SRRA,02/28/2018,Phase 1,2.75,SRA737,February 2018;
VRTX,02/28/2018,PDUFA priority review,166.24,Tezacaftor (VX-661) / ivacaftor,
IONS,03/01/2018,Phase 1/2,51.11,IONIS-HTT Rx,"February 26-March 1, 2018;"
OTIC,03/02/2018,PDUFA,5.40,OTIPRIO,
BMY,03/05/2018,PDUFA,63.48,Opdivo -  4 week applications,
PFE,03/08/2018,PDUFA,36.61,Xeljanz,
REGN,03/10/2018,Phase 3,347.86,Praluent (alirocumab) ODYSSEY OUTCOMES,
SYBX,03/11/2018,Phase 1,9.80,SYNB1020,"March 11-14, 2018;"
SLS,03/19/2018,Phase 2,5.93,Galinpepimut-S,
AMGN,03/29/2018,PDUFA,187.01,BLINCYTO,
BIIB,03/30/2018,Phase 2b,343.83,Natalizumab (α4-integrin inhibitor),Early-2018;
ABIO,03/31/2018,Phase 2b,1.68,Gencaro - GENETIC-AF trial,March 2018;
ACOR,03/31/2018,Phase 3,25.30,Tozadenant,1Q 2018;
ALT,03/31/2018,Phase 1/2,1.56,NasoVAX,1Q 2018;
ANAB,03/31/2018,Phase 2a,104.81,ANB020,1Q 2018;
ANTH,03/31/2018,Phase 3,1.56,Sollpura - RESULT,1Q 2018;
ARMO,03/31/2018,Phase 3,33.32,AM0010 (PEG-IL-10),Early 2018;
ARNA,03/31/2018,Phase 2,39.13,APD371,1Q or 2Q 2018;
ARNA,03/31/2018,Phase 2,39.13,Etrasimod,1Q 2018;
BHVN,03/31/2018,Phase 3,32.06,Rimegepant,1Q 2018;
BPTH,03/31/2018,Phase 2,0.19,Prexigebersen,Early 2018;
CDTX,03/31/2018,Phase 2,6.90,Rezafungin (CD101) IV - STRIVE,1Q 2018;
CLSD,03/31/2018,Phase 3,6.16,Suprachoroidal CLS-TA - PEACHTREE,1Q 2018;
CORT,03/31/2018,Phase 2,23.46,CORT125134,1Q 2018;
CYTK,03/31/2018,Phase 2,8.65,CK-2127107,1Q 2018;
DERM,03/31/2018,Phase 3,27.80,Olumacostat glasaretil (DRM01),1Q 2018;
EARS,03/31/2018,Phase 3,0.34,Keyzilen (AM-101) - TACTT3,1Q 2018 - likely February;
EDGE,03/31/2018,Phase 3,12.85,EG-1962,1Q 2018;
ESPR,03/31/2018,Phase 2,70.46,Bempedoic Acid - 1002-039,1Q 2018;
ESPR,03/31/2018,Phase 3,70.46,"Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046, 1002-047 and 1002-048","March, May and September 2018;"
EYEG,03/31/2018,Phase 2b,1.03,EGP-437,1Q 2018.;
FLKS,03/31/2018,Phase 2,3.83,FLX-787 (Aust),1Q 2018;
GERN,03/31/2018,Phase 2,2.51,Imetelstat - IMbarkStudy,1Q 2018;
GILD,03/31/2018,Phase 2,81.73,GS-9674,1Q 2018;
GILD,03/31/2018,Phase 3,81.73,GS-5745,1Q 2018;
GILD,03/31/2018,Phase 2,81.73,GS-9674,1Q 2018;
GILD,03/31/2018,Phase 2,81.73,Entospletinib,1Q 2018;
GLMD,03/31/2018,Phase 2,10.18,Aramchol - ARRIVE,1Q 2018;
GSK,03/31/2018,Phase 3,37.10,Dolutegravir + lamivudine (GEMINI 2),1Q 2018;
GSK,03/31/2018,Phase 3,37.10,Dolutegravir + lamivudine (GEMINI 1),1Q 2018;
GTHX,03/31/2018,Phase 2,22.97,Trilaciclib,1Q 2018;
GWPH,03/31/2018,Phase 3,133.30,Epidiolex,1Q 2018;
GWPH,03/31/2018,Phase 2,133.30,GWP42006 (CBDV),1Q 2018;
IMGN,03/31/2018,Phase 1/2,9.76,Mirvetuximab soravtansine - FORWARD II,1Q 2018;
IMGN,03/31/2018,Phase 3,9.76,Mirvetuximab soravtansine - FORWARD I,1Q 2018;
IMRN,03/31/2018,Phase 2,8.05,IMM-124E,1Q 2018;
MBIO,03/31/2018,Phase 1,11.25,MB-102,Early 2018;
MBIO,03/31/2018,Phase 1,11.25,MB-101,Early 2018;
MBVX,03/31/2018,Phase 1,0.77,MVT-1075,1Q 2018;
MBVX,03/31/2018,Phase 1/2,0.77,MVT-5873,1Q 2018;
MCRB,03/31/2018,Phase 1b,9.46,SER-262,Early 2018;
MESO,03/31/2018,Phase 2b,5.40,MPC-150-IM - Class IV,1Q 2018;
MESO,03/31/2018,Phase 3,5.40,MSC-100-IV,1Q 2018;
MRTX,03/31/2018,Phase 2,26.25,Mocetinostat and durvalumab,1Q 2018 - see note below;
MYOK,03/31/2018,Phase 2,53.05,MYK-461 - PIONEER-HCM,1Q 2018;
NBIX,03/31/2018,Phase 3,83.33,Elagolix,1Q 2018;
NVO,03/31/2018,Phase 3,50.47,Semaglutide - oral - PIONEER,1Q 2018;
OBSV,03/31/2018,Phase 2,11.00,OBE001 - IMPLANT2,1Q 2018;
PLX,03/31/2018,Phase 2,0.68,OPRX-106,1Q 2018;
PTGX,03/31/2018,Phase 2b,21.52,PTG-100,Early 2018;
PTI,03/31/2018,Phase 1,2.76,PTI-428 + Kalydeco,1Q 2018;
REGN,03/31/2018,Phase 2,347.86,Cemiplimab,1Q 2018;
RETA,03/31/2018,Phase 2,27.80,Bardoxolone methyl - LARIAT,1Q 2018;
RETA,03/31/2018,Phase 2,27.80,Omaveloxolone - MOTOR,1Q 2018;
RGLS,03/31/2018,Phase 1/2,1.25,RG-012,1Q 2018;
RNN,03/31/2018,Phase 2a,2.01,RX-3117,1Q 2018;
RNN,03/31/2018,Phase 2a,2.01,Archexin,1Q 2018;
SLS,03/31/2018,Phase 2b,5.93,NeuVax in combination with Herceptin,1Q 2018;
SPHS,03/31/2018,Phase 2,2.14,Topsalysin (PRX302),Late-1Q 2018;
SPPI,03/31/2018,Phase 3,20.57,SPI-2012 (ROLONTIS),1Q 2018;
TTPH,03/31/2018,Phase 3,5.39,Eravacycline (TP-434) - IGNITE3,1Q 2018;
VBLT,03/31/2018,Phase 3,6.35,VB-111,1Q 2018;
VNDA,03/31/2018,Phase 2,16.15,HETLIOZ (tasimelteon),1Q 2018;
VRTX,03/31/2018,Phase 2,166.24,VX-150,1Q 2018;
VTVT,03/31/2018,Phase 1/2,7.42,TTP399,Early 2018;
VTVT,03/31/2018,Phase 3,7.42,Azeliragon - STEADFAST,Early 2018;
VYGR,03/31/2018,Phase 1b,18.76,VY-AADC01,1Q 2018;
MRK,04/03/2018,PDUFA priority review,58.56,Keytruda,
THERF,04/03/2018,PDUFA,6.09,Ibalizumab,
CLVS,04/06/2018,PDUFA priority review,56.82,Rucaparib ARIEL3,
NVS,04/09/2018,Phase 3,88.39,AIN457 (Cosentyx),"April 7-10, 2018;"
EIGR,04/11/2018,Phase 2,8.20,Pegylated Interferon Lambda (LIMT HDV),EASL 2018.;
LLY,04/12/2018,PDUFA priority review,81.18,Abemaciclib - MONARCH 3,
SELB,04/13/2018,Phase 2,8.76,SEL-212,1H April 2018;
BMY,04/16/2018,PDUFA priority review,63.48,CM-214 – Opdivo + Yervoy,
RARE,04/17/2018,PDUFA priority review,49.06,KRN23 Burosumab,
RIGL,04/17/2018,PDUFA,3.97,Fostamatinib,
MNOV,04/27/2018,Phase 2,9.52,MN-166,
NBIX,04/27/2018,PDUFA priority review,83.33,Elagolix,
SCMP,04/28/2018,PDUFA,17.95,Lubiprostone,
ALKS,04/30/2018,Phase 3,63.42,ALKS 3831 - ENLIGHTEN-2,Fall 2018;
AMGN,04/30/2018,PDUFA,187.01,KYPROLIS (ENDEAVOR),
BTX,04/30/2018,Phase 1/2,2.89,OpRegen,"ARVO Conference - Apr 29 - May 03, 2018;"
KPTI,04/30/2018,Phase 2b,11.66,Selinexor - STORM,April 2018;
NBRV,04/30/2018,Phase 3,5.83,Lefamulin - LEAP 2,Spring 2018;
NVS,04/30/2018,PDUFA priority review,88.39,Kymriah (CTL019 )- JULIET,
PGNX,04/30/2018,PDUFA priority review,5.41,Azedra,
SGEN,05/01/2018,PDUFA priority review,55.90,ADCETRIS  in combination with chemotherapy ECHELON-1,
PTLA,05/04/2018,PDUFA,49.88,Andexanet alfa,
LPCN,05/08/2018,PDUFA,1.33,LPCN 1021,
AZN,05/15/2018,PDUFA priority review,35.90,Tagrisso - FLAURA,Estimate mid-2Q 2018;
AMGN,05/17/2018,PDUFA,187.01,Erenumab,
NVS,05/17/2018,PDUFA,88.39,Erenumab,
DOVA,05/21/2018,PDUFA priority review,30.74,Avatrombopag,
JNJ,05/21/2018,PDUFA priority review,137.68,DARZALEX (Daratumumab) - ALCYONE,
BMRN,05/25/2018,PDUFA priority review,90.82,Pegvaliase,
REPH,05/26/2018,PDUFA,8.30,Intravenous (IV) meloxicam,
AMGN,05/28/2018,PDUFA,187.01,Prolia (denosumab),
TXMD,05/29/2018,PDUFA,5.51,Yuvvexy - TX-004HR,
ESPR,05/31/2018,Phase 3,70.46,Bempedoic acid (ETC-1002-040) - Clear Harmony,May 2018;
KTOV,05/31/2018,PDUFA,2.66,KIT-302,
NVS,05/31/2018,PDUFA priority review,88.39,Tafinlar (dabrafenib) and Mekinist (trametinib),Estimate mid-2Q 2018;
IDRA,06/01/2018,Phase 2,1.80,IMO-2125 + ipilimumab - ILLUMINATE 204,ASCO 2018;
VRX,06/18/2018,PDUFA,18.00,IDP-118,
SCPH,06/23/2018,PDUFA,12.28,Furoscix,
AKAO,06/25/2018,PDUFA priority review,10.74,Plazomicin,
GWPH,06/27/2018,PDUFA priority review,133.30,Epidiolex,
ABBV,06/30/2018,Phase 2,115.17,Rova-T (TRINITY),2Q 2018;
ACRS,06/30/2018,Phase 2,20.96,ATI-50002 - PK/safety,1H 2018;
ACRS,06/30/2018,Phase 2,20.96,ATI-50002 - open label,1H 2018;
AGN,06/30/2018,Phase 2,172.51,Brimo DDS,1H 2018;
AGN,06/30/2018,Phase 2b,172.51,ATOGEPANT,1H 2018;
AGN,06/30/2018,Phase 3,172.51,UBROGEPANT,1H 2018;
AGN,06/30/2018,PDUFA,172.51,ESMYA  (ulipristal acetate),1H 2018;
ALRN,06/30/2018,Phase 2a,9.00,ALRN-6924,1H 2018;
ANAB,06/30/2018,Phase 2a,104.81,ANB020,2Q 2018;
ANIK,06/30/2018,Phase 3,64.60,Cingal,1H 2018;
APLS,06/30/2018,Phase 3,16.45,APL-2 IV - FILLY,1H 2018;
ARGS,06/30/2018,Phase 3,1.92,rocapuldencel-T (AGS-003) ADAPT Trial,1H 2018;
ARGS,06/30/2018,Phase 1,1.92,AGS-004 and vorinostat,1H 2018;
ARRY,06/30/2018,PDUFA,14.88,Binimetinib - COLUMBUS,
ASNS,06/30/2018,Phase 2,12.33,ASN100,1H 2018;
AVEO,06/30/2018,Phase 3,2.99,TIVO-3 - tivozanib,2Q 2018;
AVIR,06/30/2018,Phase 2,0.61,BTA074 5% topical gel,2Q 2018;
AXON,06/30/2018,Phase 2,1.92,Nelotanserin,2Q 2018;
AXSM,06/30/2018,Phase 3,2.70,AXS-05 STRIDE-1,1H 2018;
AZN,06/30/2018,Phase 3,35.90,Selumetinib - ASTRA,1H 2018;
AZN,06/30/2018,Phase 3,35.90,Lynparza,1H 2018;
AZN,06/30/2018,Phase 3,35.90,Durvalumab +/- tremelimumab (MYSTIC),1H 2018;
AZN,06/30/2018,Phase 3,35.90,Durvalumab +/- tremelimumab (KESTREL),1H 2018;
AZN,06/30/2018,Phase 3,35.90,Durvalumab +/- tremelimumab (EAGLE),1H 2018;
AZN,06/30/2018,Phase 3,35.90,Durvalumab +/- tremelimumab (ARCTIC),1H 2018;
BMY,06/30/2018,Phase 3,63.48,CM-714 Opdivo + Yervoy,1H 2018;
BMY,06/30/2018,Phase 3,63.48,CM-511 – Opdivo + Yervoy,1H 2018;
BMY,06/30/2018,Phase 3,63.48,CM-331– Opdivo,1H 2018;
BMY,06/30/2018,Phase 3,63.48,CM-227 – Opdivo + Yervoy,1H 2018;
BMY,06/30/2018,Phase 2,63.48,CM-548 - Opdivo+SOC,1H 2018;
BOLD,06/30/2018,Phase 1/2,34.22,AT342 - VALENS,2Q 2018;
CBIO,06/30/2018,Phase 2,25.27,Marzeptacog alfa,1H 2018;
CELG,06/30/2018,Phase 3,99.80,REVLIMID - AUGMENT NHL-007,1H 2018;
CKPT,06/30/2018,Phase 1/2,4.26,CK-101,1H 2018;
CLDX,06/30/2018,Phase 2b,2.67,Glembatumumab vedotin,2Q 2018;
CLSD,06/30/2018,Phase 2,6.16,Suprachoroidal CLS-TA - TYBEE,2Q 2018;
CLSD,06/30/2018,Phase 1/2,6.16,Suprachoroidal CLS-TA - HULK,2Q 2018;
CNAT,06/30/2018,Phase 2b,5.17,Emricasan,1H 2018;
CORI,06/30/2018,Phase 1,12.31,Corplex Donepezil,1H 2018;
CPRX,06/30/2018,Phase 3,3.30,Firdapse,1H 2018;
CTIC,06/30/2018,Phase 3,2.83,PIXUVRI - PIX306 Trial,1H 2018;
DBVT,06/30/2018,Phase 2b,22.64,Viaskin Milk,1H 2018;
DERM,06/30/2018,PDUFA,27.80,Glycopyrronium tosylate (DRM04),
DNLI,06/30/2018,Phase 1,20.39,DNL201,1H 2018;
EXEL,06/30/2018,Phase 3,30.22,IMblaze370 - cobimetinib and atezolizumab,1H 2018;
EYEG,06/30/2018,Phase 3,1.03,EGP-437,2Q 2018;
FBIO,06/30/2018,Phase 2,3.72,CEVA101,1H 2018;
FBIO,06/30/2018,Phase 2,3.72,Pepvax vaccine,1H 2018;
FBIO,06/30/2018,Phase 3,3.72,IV Tramadol,2Q 2018;
GEMP,06/30/2018,Phase 2b,9.58,Gemcabene - INDIGO-1,2Q 2018;
GILD,06/30/2018,Phase 2,81.73,Selonsertib (GS-4997),2Q 2018;
GLMD,06/30/2018,Phase 2b,10.18,Aramchol - ARREST,2Q 2018;
GLPG,06/30/2018,Phase 2,118.00,GLPG2737 - PELICAN,1H 2018;
GLPG,06/30/2018,Phase 2,118.00,Filgotinib - TORTUGA,2Q 2018;
GLPG,06/30/2018,Phase 2,118.00,Filgotinib - EQUATOR,2Q 2018;
GTHX,06/30/2018,Phase 1b,22.97,G1T38 plus Faslodex,2Q 2018;
HRTX,06/30/2018,Phase 3,21.65,HTX-011,1H 2018;
IDRA,06/30/2018,Phase 2,1.80,IMO-8400,2Q 2018;
IMMP,06/30/2018,Phase 1,1.76,Eftilagimod alpha and Keytruda,1H 2018;
INCY,06/30/2018,Phase 3,85.92,Epacadostat with Keytruda - ECHO-301,1H 2018;
INCY,06/30/2018,Phase 3,85.92,Ruxolitinib - REACH 1,1H 2018;
INFI,06/30/2018,Phase 1,2.01,IPI-549 + Nivolumab,2Q 2018;
JNCE,06/30/2018,Phase 1/2,23.37,JTX-2011,1H 2018;
JNJ,06/30/2018,Phase 3,137.68,Esketamine,2018;
KMPH,06/30/2018,Phase 3,6.35,KP415,2Q 2018;
KURA,06/30/2018,Phase 2,19.80,Tipifarnib,1H 2018;
MACK,06/30/2018,Phase 2,10.50,MM-141 - CARRIE,1H 2018;
MDWD,06/30/2018,Phase 3,4.35,NexoBrid,1H 2018;
MEIP,06/30/2018,Phase 2,2.17,Pracinostat in combination with Vidaza,1H 2018;
MGNX,06/30/2018,Phase 2,21.86,Margetuximab in combination with pembrolizumab,1H 2018;
MNLO,06/30/2018,Phase 2,30.56,Serlopitant,2Q 2018;
MRK,06/30/2018,Phase 3,58.56,(MK-3475-189/KEYNOTE-189),"1H 2018 (est, only);"
MTNB,06/30/2018,Phase 2,0.95,MAT2501,2Q 2018;
NBIX,06/30/2018,Phase 2a,83.33,NBI-74788,1H 2018;
NLNK,06/30/2018,Phase 2,8.45,Indoximod + gemcitabine and nab-paclitaxel,1H 2018;
NVS,06/30/2018,Phase 2,88.39,LJN452,1H 2018;
NVS,06/30/2018,Phase 3,88.39,LEE011: MONALEESA-3,2Q 2018;
PBYI,06/30/2018,Phase 3,64.35,Neratinib,1H 2018;
PFNX,06/30/2018,Phase 3,3.36,PF708 and Forteo,1H 2018;
PRTA,06/30/2018,Phase 2b,39.60,NEOD001 PRONTO,2Q 2018;
PSTI,06/30/2018,Phase 2,1.42,PLX-PAD (stem cells),1H 2018;
RNN,06/30/2018,Phase 2a,2.01,Supinoxin,2Q 2018;
RXDX,06/30/2018,Phase 1b,26.95,RXDX-105,1H 2018;
RXII,06/30/2018,Phase 2,3.94,Samcyprone - RXI-SCP-1502,1Q/2Q 2018;
RYTM,06/30/2018,Phase 2,29.54,Setmelanotide,1H 2018;
SAGE,06/30/2018,Phase 2,186.78,SAGE-217,2Q 2018;
SBBP,06/30/2018,Phase 3,6.80,COR-003 (levoketoconazole) - SONICS,2Q 2018;
SGMO,06/30/2018,Phase 1/2,19.65,SB-525 cDNA gene therapy,1H 2018;
SGMO,06/30/2018,Phase 1/2,19.65,SB-318,1H 2018;
SGMO,06/30/2018,Phase 1/2,19.65,SB-913 - CHAMPIONS,1H 2018;
SNDX,06/30/2018,Phase 1/2,11.14,Entinostat plus Keytruda - ENCORE 601,1H 2018;
SNDX,06/30/2018,Phase 3,11.14,E2112,1H 2018;
SPRO,06/30/2018,Phase 1b,12.09,SPR741,1H 2018;
SVRA,06/30/2018,Phase 2,11.45,Aironite - INDIE,1H 2018;
TBPH,06/30/2018,Phase 2a,24.68,TD-9855,1H 2018;
TCON,06/30/2018,Phase 1/2,2.80,TRC253,1H 2018;
TCON,06/30/2018,Phase 2,2.80,TRC105 and Inlyta,1H 2018;
TGTX,06/30/2018,Phase 3,11.80,TG-1101 and TGR-1202 - UNITY-CLL study,2Q 2018;
TOCA,06/30/2018,Phase 2/3,12.48,Toca 511 & Toca FC,1H 2018;
TPIV,06/30/2018,Phase 2,3.53,TPIV200,1H 2018;
TSRO,06/30/2018,Phase 1/2,59.94,Niraparib and Keytruda (TOPACIO),1H 2018;
TTNP,06/30/2018,Phase 1/2,1.33,Ropinirole implant,1H 2018;
VICL,06/30/2018,Phase 2,1.48,VCL-HB01 HSV-2 Therapeutic Vaccine,2Q 2018;
VKTX,06/30/2018,Phase 2,6.07,VK2809,1H 2018;
VRNA,06/30/2018,Phase 2a,12.10,RPL554,1H 2018;
VRTX,06/30/2018,Phase 2,166.24,VX-445 in combination with tezacaftor and ivacaftor,1H 2018;
XLRN,06/30/2018,Phase 2,40.81,ACE-083,1H 2018;
ZEAL,06/30/2018,Phase 3,16.34,Dasiglucagon,2Q 2018;
ZGNX,06/30/2018,Phase 3,37.00,ZX008 - Study 1504,2Q 2018;
IONS,07/06/2018,PDUFA priority review,51.11,Inotersen (IONIS-TTRRx),
DRRX,07/28/2018,PDUFA,1.13,RBP-7000,
INSY,07/28/2018,PDUFA,8.80,Buprenorphine,
ALNY,07/31/2018,Phase 3,124.50,Givosiran,Mid-2018;
ALXN,07/31/2018,Phase 3,116.15,Eculizumab,Mid-2018;
ATNX,07/31/2018,Phase 3,14.43,Oraxol,Mid-2018;
BLRX,07/31/2018,Phase 2,1.05,BL-8040,Mid-2018;
CMTX,07/31/2018,Phase 2,10.00,CX-072,Mid-2018;
CTMX,07/31/2018,Phase 1/2,26.93,CX 072,Mid-2018;
EBIO,07/31/2018,Phase 3,0.88,Vicinium,Mid-2018;
FOMX,07/31/2018,Phase 3,6.57,FMX103,Mid-2018;
FOMX,07/31/2018,Phase 3,6.57,FMX101 - FX2017-22,Mid-2018;
GNMX,07/31/2018,Phase 2,2.16,AEVI-001 (NFC-1),Mid-2018;
GNMX,07/31/2018,Phase 1/2,2.16,AEVI-002 (Anti-LIGHT mAb),Mid-2018;
JUNO,07/31/2018,Phase 1/2,85.60,Lico-cel (CD-19 JCAR017) - TRANSCEND,2018;
MRTX,07/31/2018,Phase 2,26.25,Sitravatinib plus nivolumab,Mid-2018;
OBSV,07/31/2018,Phase 2b,11.00,OBE2109 - EDELWEISS,Mid-2018;
PULM,07/31/2018,Phase 1,1.63,Pulmazole (PUR1900),Mid-2018;
RDHL,07/31/2018,Phase 3,5.84,RHB-104 MAP US,Mid-2018;
SCYX,07/31/2018,Phase 2b,1.77,SCY-078 - oral,Mid-2018;
SNSS,07/31/2018,Phase 1/2,5.82,SNS-062,Mid-2018;
SPRO,07/31/2018,Phase 1,12.09,SPR994,Mid-2018;
SRPT,07/31/2018,Phase 1/2,63.12,SRP-5051,Mid-2018;
VRNA,07/31/2018,Phase 2b,12.10,RPL554,Mid-2018;
XLRN,07/31/2018,Phase 3,40.81,Luspatercept - BELIEVE,Mid-2018;
XLRN,07/31/2018,Phase 3,40.81,Luspatercept - MEDALIST,Mid-2018;
ZFGN,07/31/2018,Phase 2,7.51,ZGN-1061,Mid-2018;
ALNY,08/11/2018,PDUFA priority review,124.50,Patisiran APOLLO,
REGN,08/11/2018,PDUFA,347.86,EYLEA,
KALA,08/24/2018,PDUFA,14.71,INVELTYS,
VRX,08/26/2018,PDUFA,18.00,IDP-121,
AKCA,08/30/2018,PDUFA,22.70,Volanesorsen - APPROACH,
AGLE,09/30/2018,Phase 1/2,6.59,AEB1102,3Q 2018;
AGTC,09/30/2018,Phase 1/2,4.30,rAAV-hRS1,3Q 2018 est.;
AMRN,09/30/2018,Phase 3,3.76,Vascepa REDUCE-IT outcomes trial,3Q 2018;
AQXP,09/30/2018,Phase 3,13.38,AQX-1125 LEADERSHIP,3Q 2018;
CNCE,09/30/2018,Phase 3,20.01,AVP-786,3Q 2018;
EIGR,09/30/2018,Phase 2,8.20,Exendin 9-39,3Q 2018;
FLKS,09/30/2018,Phase 2,3.83,FLX-787 - COMMEND US trial,3Q 2018;
GILD,09/30/2018,Phase 3,81.73,F/TAF (Descovy),3Q 2018;
HSGX,09/30/2018,Phase 3,2.84,NeoCart,3Q 2018;
NVO,09/30/2018,Phase 2,50.47,Concizumab - explorer,3Q 2018;
NVO,09/30/2018,Phase 3,50.47,Somapacitan (NN8640) - REAL 3,3Q 2018;
NVS,09/30/2018,Phase 2,88.39,INC280,3Q 2018;
PGNX,09/30/2018,Phase 3,5.41,1404,3Q 2018;
RGLS,09/30/2018,Phase 2,1.25,RG-012 - HERA,3Q 2018;
SMMT,09/30/2018,Phase 2,12.41,Ezutromid,3Q 2018;
TNXP,09/30/2018,Phase 3,3.54,TNX-102 SL,3Q 2018;
URGN,09/30/2018,Phase 3,48.18,MitoGel - OLYMPUS,3Q 2018;
VTL,09/30/2018,Phase 3,5.85,VTI-308,3Q 2018;
LLY,10/10/2018,PDUFA,81.18,"Galcanezumab - EVOLVE-1, EVOLVE-2 and REGAIN",
PRTK,10/19/2018,PDUFA,14.55,Sarecycline,4Q 2018;
MRK,10/23/2018,PDUFA,58.56,Doravirine (MK-1439),
TRVN,11/02/2018,PDUFA,1.56,Oliceridine (TRV130),
NVS,11/16/2018,PDUFA,88.39,Adalimumab,"Nov 16, 2018 est only;"
TBPH,11/30/2018,PDUFA,24.68,Revefenacin,
ABBV,12/31/2018,Phase 3,115.17,ABT-494 - SELECT-COMPARE,2018;
ABBV,12/31/2018,Phase 3,115.17,Imbruvica - PHOENIX,2018;
ABLX,12/31/2018,Phase 2b,54.57,ALX-0171,2H 2018;
ABUS,12/31/2018,Phase 2,5.00,"ARB-1467, tenofovir, and pegylated interferon",2H 2018;
ACIU,12/31/2018,Phase 1/2,12.63,ACI-24 (anti-Abeta vaccine),2018;
ACRS,12/31/2018,Phase 2,20.96,ATI-50002 - dose ranging,YE 2018;
ADVM,12/31/2018,Phase 1/2,7.30,ADVM-043,2H 2018;
AGN,12/31/2018,Phase 2b,172.51,Brazikumab,2018;
AGN,12/31/2018,Phase 3,172.51,ABICIPAR,2H 2018;
AIMT,12/31/2018,Phase 3,36.18,AR101 RAMSES,2H 2018;
AKBA,12/31/2018,Phase 3,14.56,Vadadustat - TRILO2GY,YE 2018;
AKBA,12/31/2018,Phase 2,14.56,Vadadustat - FO2RWARD,YE 2018;
AKCA,12/31/2018,Phase 2,22.70,AKCEA-ANGPTL3-LRx,2018;
AKCA,12/31/2018,Phase 2b,22.70,AKCEA-APO(a)-LRx,2018;
ALDX,12/31/2018,Phase 2b,7.10,ADX-102,2H 2018;
ALDX,12/31/2018,Phase 2b,7.10,ADX-102,2H 2018;
ALDX,12/31/2018,Phase 3,7.10,ADX-102,2H 2018;
ALDX,12/31/2018,Phase 2,7.10,ADX-102,2H 2018;
ALNA,12/31/2018,Phase 2,8.69,ALLN-177,2H 2018;
ALNY,12/31/2018,Phase 1/2,124.50,ALN-CC5 (cemdisiran),2018;
ALXN,12/31/2018,Phase 1/2,116.15,ALXN1210,2Q 2018;
AMGN,12/31/2018,Phase 3,187.01,ABP 710,2H 2018;
APLS,12/31/2018,Phase 2,16.45,APL-2 subcutaneous,2H 2018;
ARGX,12/31/2018,Phase 2,72.97,ARGX-113,2H 2018;
ARGX,12/31/2018,Phase 2,72.97,ARGX-113,2H 2018;
ARMO,12/31/2018,Phase 2b,33.32,AM0010 (PEG-IL-10) and Pembrolizumab - Cypress 1,YE 2018;
ARMO,12/31/2018,Phase 2b,33.32,AM0010 (PEG-IL-10) and Nivolumab - Cypress 2,YE 2018;
AST,12/31/2018,Phase 1/2,2.00,AST-VAC2,2H 2018;
ATNM,12/31/2018,Phase 1,0.63,Actimab-M,2H 2018;
ATOS,12/31/2018,Phase 2,0.67,Endoxifen,2018;
ATOS,12/31/2018,Phase 2,0.67,Endoxifen,2018;
AUPH,12/31/2018,Phase 2,5.04,Voclosporin,2H 2018;
AUPH,12/31/2018,Phase 2,5.04,Voclosporin,2H 2018;
AZN,12/31/2018,Phase 3,35.90,Lynparza,2H 2018;
AZN,12/31/2018,Phase 3,35.90,Farxiga - DECLARE,2H 2018;
AZN,12/31/2018,Phase 3,35.90,FASENRA (benralizumab) - TERRANOVA,2H 2018;
AZN,12/31/2018,Phase 3,35.90,Durvalumab +/- tremelimumab (NEPTUNE),2H 2018;
AZN,12/31/2018,Phase 3,35.90,Anifrolumab,2H 2018;
BIIB,12/31/2018,Phase 2,343.83,Raxatrigine - BIIB074 (Nav1.7 inhibitor),2018;
BIIB,12/31/2018,Phase 2,343.83,BAN2401 (Aβ mAb),2H 2018;
BIVV,12/31/2018,Phase 1/2,103.99,BIVV001 (EXTEN-A),2018;
BLPH,12/31/2018,Phase 2b,2.27,INOpulse delivery device,YE 2018;
BLPH,12/31/2018,Phase 2,2.27,INOpulse delivery device,YE 2018;
BLPH,12/31/2018,Phase 3,2.27,INOpulse delivery device,2018;
BLRX,12/31/2018,Phase 2,1.05,BL-8040 in combination with KEYTRUDA - COMBAT trial,
BLRX,12/31/2018,Phase 2b,1.05,BL-8040,2018;
BMY,12/31/2018,Phase 3,63.48,CM-602 – Opdivo + Elo + SOC,2H 2018;
BMY,12/31/2018,Phase 3,63.48,CM-459 – Opdivo,2H 2018;
BMY,12/31/2018,Phase 3,63.48,CM-451 – Opdivo + Yervoy,2H 2018;
BYSI,12/31/2018,Phase 3,26.92,Plinabulin,2018;
CANF,12/31/2018,Phase 2,2.29,Namodenoson (CF102),2H 2018;
CASC,12/31/2018,Phase 2,9.96,Tucatinib - MOUNTAINEER,2018;
CELG,12/31/2018,Phase 3,99.80,OTEZLA - SPSO-001,2018;
CELG,12/31/2018,Phase 3,99.80,REVLIMID - ROBUST,2018;
CELG,12/31/2018,Phase 3,99.80,MM-007 OPTIMISMM,2018;
CELG,12/31/2018,Phase 3,99.80,Oral Azacitidine - CC-486-AML-001,2H 2018;
CELG,12/31/2018,Phase 3,99.80,ABRAXANE - PANC-003 apact,2018;
CELG,12/31/2018,Phase 3,99.80,ABRAXANE - IMpower 130 ( I/O Combo),2018;
CELG,12/31/2018,Phase 3,99.80,ABRAXANE - IMpower 131 ( I/O Combo),2018;
CELG,12/31/2018,Phase 3,99.80,ABRAXANE - IMPassion ( I/O Combo),2018;
CFRX,12/31/2018,Phase 2,1.41,CF-301,4Q 2018;
CMRX,12/31/2018,Phase 2,4.70,IV Brincidofovir,2H 2018;
CMTX,12/31/2018,Phase 2,10.00,CX-2009 - PROCLAIM,2H 2018;
CNAT,12/31/2018,Phase 2,5.17,Emricasan,2H 2018;
CNCE,12/31/2018,Phase 2a,20.01,CTP-543,2H 2018;
CTMX,12/31/2018,Phase 1/2,26.93,CX 2009,2H 2018;
DCPH,12/31/2018,Phase 1,26.12,DCC-3014,2H 2018;
EGRX,12/31/2018,Phase 3,58.37,Fulvestrant,4Q 2018;
EIGR,12/31/2018,Phase 2,8.20,Ubenimex - ULTRA,2H 2018;
EPZM,12/31/2018,Phase 2,16.85,Tazemetostat,2018;
ESPR,12/31/2018,Phase 3,70.46,Bempedoic Acid/ Ezetimibe (1002FDC-053),4Q 2018;
FGEN,12/31/2018,Phase 3,55.75,Roxadustat - ANDES,2H 2018;
FLKS,12/31/2018,Phase 2,3.83,FLX-787,2018;
FLXN,12/31/2018,Phase 2,21.60,Zilretta - SHIP,2H 2018;
GEMP,12/31/2018,Phase 2,9.58,Gemcabene - AZURE-1,2H 2018;
GILD,12/31/2018,Phase 2,81.73,Tirabrutinib (GS-4059),2H 2018;
GILD,12/31/2018,Phase 2,81.73,GS-9876,2H 2018;
GILD,12/31/2018,Phase 2,81.73,GS-5734,2H 2018;
GILD,12/31/2018,Phase 2,81.73,Axicabtagene ciloleucel - KTE-C19 (ZUMA-2),2018;
GILD,12/31/2018,Phase 1/2,81.73,Axicabtagene ciloleucel - KTE-C19 (ZUMA-3),2018;
GILD,12/31/2018,Phase 1/2,81.73,Axicabtagene ciloleucel - KTE-C19 (ZUMA-4),2018;
GLYC,12/31/2018,Phase 3,22.33,GMI-1070 (rivipansel),2018;
GTHX,12/31/2018,Phase 2,22.97,Trilaciclib,4Q 2018;
GTXI,12/31/2018,Phase 2,14.31,Enobosarm,YE 2018;
GWPH,12/31/2018,Phase 3,133.30,Epidiolex,2H 2018;
GWPH,12/31/2018,Phase 3,133.30,Epidiolex,2H 2018;
HALO,12/31/2018,Phase 3,18.37,PEGPH20 - HALO-301,Late 4Q 2018;
HALO,12/31/2018,Phase 1b,18.37,PEGPH20 in combination with KEYTRUDA,2018;
IMGN,12/31/2018,Phase 3,9.76,Kadcyla (KATHERINE).,2018;
IMRN,12/31/2018,Phase 2,8.05,IMM-124E,4Q 2018;
IMRN,12/31/2018,Phase 1/2,8.05,IMM-529,4Q 2018;
INSY,12/31/2018,Phase 2,8.80,Cannabidiol,YE 2018;
JNJ,12/31/2018,Phase 3,137.68,STELARA (USTEKINUMAB),2018;
JUNO,12/31/2018,Phase 1,85.60,JCARH125,2018;
KPTI,12/31/2018,Phase 2b,11.66,Selinexor - SADAL,2H 2018;
LLY,12/31/2018,Phase 3,81.18,Ramucirumab,2018;
LLY,12/31/2018,Phase 3,81.18,Ramucirumab,2018;
LLY,12/31/2018,Phase 3,81.18,Empagliflozin,2018;
LLY,12/31/2018,Phase 3,81.18,Ixekizumab,2018;
LLY,12/31/2018,–,81.18,Tradjenta (linagliptin) - CARMELINA CV outcomes,2018;
LLY,12/31/2018,Phase 3,81.18,Ultra rapid insulin,2018;
LLY,12/31/2018,Phase 3,81.18,Tanezumab,2018;
LLY,12/31/2018,Phase 3,81.18,Ramucirumab,2018;
LLY,12/31/2018,Phase 3,81.18,Flortaucipir F 18 (Tau imaging agent),2018;
MACK,12/31/2018,Phase 2,10.50,MM-121 (SHERBOC),2H 2018;
MACK,12/31/2018,Phase 2,10.50,MM-121,2H 2018;
MBRX,12/31/2018,Phase 1/2,1.79,Annamycin,2018;
MNLO,12/31/2018,Phase 2,30.56,Serlopitant,Late 2018 or early 2019;
MNLO,12/31/2018,Phase 2,30.56,Serlopitant,Late 2018 or early 2019;
MRNS,12/31/2018,Phase 2,6.92,Ganaxolone,2018;
NBIX,12/31/2018,Phase 2b,83.33,INGREZZA - T-Force GOLD,Late-2018;
NCNA,12/31/2018,Phase 1,23.13,NUC-3373,2018;
NCNA,12/31/2018,Phase 2,23.13,NUC-1031 (Acelarin),2018;
NITE,12/31/2018,Phase 1/2,14.70,NSR-RPGR,2018;
NVAX,12/31/2018,Phase 3,2.00,RSV vaccine - prepare trial,4Q 2018 or 1Q 2019;
NVCR,12/31/2018,Phase 2,21.30,Tumor Treating Fields (TTFields) STELLAR,2018;
NVS,12/31/2018,Phase 3,88.39,BYL719,2H 2018;
NVS,12/31/2018,Phase 2,88.39,LIK066,2H 2018;
NVS,12/31/2018,Phase 3,88.39,Entresto - PARAGON,2H 2018;
OBSV,12/31/2018,Phase 2a,11.00,OBE022 - PROLONG,YE 2018;
OCUL,12/31/2018,Phase 3,5.18,OTX-TP,2H 2018;
ONCS,12/31/2018,Phase 2b,1.66,ImmunoPulse IL-12 - PISCES,2018;
OVID,12/31/2018,Phase 2,8.40,OV101 (STARS),2H 2018;
PIRS,12/31/2018,Phase 2a,8.07,PRS-080,2H 2018;
PRQR,12/31/2018,Phase 1/2,3.18,QR-010,2018;
PULM,12/31/2018,Phase 2a,1.63,PUR1800,4Q 2018;
QURE,12/31/2018,Phase 3,18.22,AMT-061,YE 2018;
RARE,12/31/2018,Phase 1/2,49.06,DTX301,2H 2018;
RDHL,12/31/2018,Phase 3,5.84,RHB-105 - ERADICATE Hp 2,2H 2018;
REGN,12/31/2018,Phase 3,347.86,Dupixent (dupilumab),2018;
RETA,12/31/2018,Phase 3,27.80,Bardoxolone methyl - CATALYST,2H 2018;
RGNX,12/31/2018,Phase 1/2,24.80,RGX-501,Late 2018;
RIGL,12/31/2018,Phase 2,3.97,Fostamatinib,2018;
RVNC,12/31/2018,Phase 3,31.50,"RT002 - SAKURA 1, 2 and 3",2H 2018;
SBBP,12/31/2018,Phase 3,6.80,COR-003 (levoketoconazole) - LOGICS,4Q 2018;
SCYX,12/31/2018,Phase 3,1.77,SCY-078 - oral - CARES,4Q 2018;
SCYX,12/31/2018,Phase 3,1.77,SCY-078 - oral (FURI),4Q 2018;
SGEN,12/31/2018,Phase 3,55.90,ADCETRIS in combination with chemotherapy - ECHELON-2,2018;
SGMO,12/31/2018,Phase 1/2,19.65,SB-FIX,2018;
SNGX,12/31/2018,Phase 3,2.12,SGX301 (synthetic hypericin),2H 2018;
SNNA,12/31/2018,Phase 3,16.61,SNA-001,2H 2018;
SNNA,12/31/2018,Phase 3,16.61,SNA-001,2H 2018;
SNY,12/31/2018,Phase 3,43.22,Isatuximab,4Q 2018;
SRPT,12/31/2018,Phase 1/2,63.12,Microdystrophin gene therapy rAAVrh74.MCK.GALGT2,2H 2018;
SRPT,12/31/2018,Phase 1/2,63.12,GALGT2 gene therapy,2H 2018;
SVRA,12/31/2018,Phase 3,11.45,Molgradex - IMPALA,YE 2018;
SYBX,12/31/2018,Phase 1,9.80,SYNB1618,2H 2018;
SYBX,12/31/2018,Phase 1/2,9.80,SYNB1020,YE 2018;
TBPH,12/31/2018,Phase 3,24.68,Closed Triple - CAPTAIN,2H 2018;
TCON,12/31/2018,Phase 2,2.80,TRC105,2018;
TCON,12/31/2018,Phase 2,2.80,TRC102,2018;
TCON,12/31/2018,Phase 3,2.80,TRC105 (TAPPAS),2H 2018;
TORC,12/31/2018,Phase 2b,17.04,RTB101 and Everolimus,2H 2018;
TSRO,12/31/2018,Phase 1/2,59.94,Niraparib - AVANOVA,2H 2018;
UTHR,12/31/2018,Phase 3,133.31,Esuberaprost - BEAT,2018;
UTHR,12/31/2018,Phase 3,133.31,Orenitram,2H 2018;
VNDA,12/31/2018,Phase 2,16.15,Tradipitant,YE 2018;
VNDA,12/31/2018,Phase 3,16.15,HETLIOZ (tasimelteon),2018;
VTGN,12/31/2018,Phase 2,1.16,AV-101,2H 2018;
XBIT,12/31/2018,Phase 2,4.54,XBIO-101,YE 2018;
XNCR,12/31/2018,Phase 2,21.54,XmAb5871,4Q 2018;
ZEAL,12/31/2018,Phase 3,16.34,Dasiglucagon,2H 2018;
AIMT,03/31/2019,Phase 3,36.18,AR101 ARTEMIS,Early 2019;
ASND,03/31/2019,Phase 3,49.79,TransCon,1Q 2019;
CLBS,03/31/2019,Phase 2,4.22,CLBS03,Early 2019;
CLSD,03/31/2019,Phase 3,6.16,Suprachoroidal CLS-TA - SAPPHIRE,1Q 2019;
CLSN,03/31/2019,Phase 3,2.35,ThermoDox - OPTIMA,1Q 2019;
CTXR,03/31/2019,Phase 3,3.93,Mino-Lok,Early 2019;
EVFM,03/31/2019,Phase 3,8.65,Amphora - AMPOWER,1Q 2019;
GSK,03/31/2019,Phase 2b,37.10,Danirixin,1Q 2019;
IMRN,03/31/2019,Phase 1/2,8.05,IMM-529,1Q 2019;
ORMP,03/31/2019,Phase 2b,7.98,ORMD-0801,Early 2019;
PRTO,03/31/2019,Phase 3,2.25,Vonapanitase (PRT-201) PATENCY-2,1Q 2019;
RNN,03/31/2019,Phase 2a,2.01,RX-3117 in combination with Abraxane,1Q 2019;
ATRA,06/30/2019,Phase 1,33.05,ATA188,1H 2019;
ATRA,06/30/2019,Phase 3,33.05,ATA 129 - ALLELE,1H 2019;
BMY,06/30/2019,Phase 2,63.48,CM-568 - Opdivo + Yervoy,2H 2018 – 1H 2019;
CMRX,06/30/2019,–,4.70,Oral Brincidofovir,1H 2019;
CNAT,06/30/2019,Phase 2,5.17,Emricasan,1H 2019;
DERM,06/30/2019,Phase 2b,27.80,Lebrikizumab,1H 2019;
FBIO,06/30/2019,Phase 2,3.72,CEVA101,1H 2019;
GBT,06/30/2019,Phase 3,60.80,GBT440 - HOPE,1H 2019;
GSK,06/30/2019,Phase 3,37.10,Tapinarof (GSK2894512),1H 2019;
GSK,06/30/2019,Phase 2b,37.10,Inhaled PI3Kδ inhibitor,1H 2019;
ICPT,06/30/2019,Phase 3,62.87,Ocaliva (Obeticholic acid (OCA)) - REGENERATE,1H 2019;
KMDA,06/30/2019,Phase 1/2,5.20,Alpha-1 antitrypsin (AAT),1H 2019;
NERV,06/30/2019,Phase 3,6.20,MIN-101,1H 2019;
RARX,06/30/2019,Phase 2,7.02,RA101495,1H 2019;
RYTM,06/30/2019,Phase 3,29.54,Setmelanotide,1H 2019;
SLDB,06/30/2019,Phase 1/2,29.00,SGT-001,1H 2019;
SNDX,06/30/2019,Phase 1/2,11.14,Entinostat plus Tecentriq - ENCORE 603,1H 2019;
SNGX,06/30/2019,Phase 3,2.12,SGX942 (dusquetide),1H 2019;
SNNA,06/30/2019,Phase 2b,16.61,SNA-120,1H 2019;
TBPH,06/30/2019,Phase 3,24.68,Telavancin,2018/19;
TGTX,06/30/2019,Phase 2/3,11.80,TG-1101 and TGR-1202 - UNITY-NHL study,1H 2019;
VTGN,06/30/2019,Phase 2,1.16,AV-101,1H 2019;
ALNY,10/31/2019,Phase 3,124.50,Fitusiran (ATLAS),Mid-late 2019;
ABBV,12/31/2019,Phase 3,115.17,Venetoclax,2019;
ADXS,12/31/2019,Phase 1/2,2.90,Axalimogene filolisbac + durvalumab,2019;
AFMD,12/31/2019,Phase 2,1.88,AFM13,2019;
AGN,12/31/2019,Phase 3,172.51,RAPASTINEL,2019;
AKBA,12/31/2019,Phase 3,14.56,Vadadustat - INNO2VATE,2019;
AKBA,12/31/2019,Phase 3,14.56,Vadadustat - PRO2TECT,2019;
AKCA,12/31/2019,Phase 2,22.70,AKCEA-ANGPTL3-LRx,2019;
AKCA,12/31/2019,Phase 2b,22.70,AKCEA-APOCIII-LRx,2019;
ALNA,12/31/2019,Phase 3,8.69,ALLN-177,2H 2019;
AMGN,12/31/2019,Phase 3,187.01,KYPROLIS (ARROW),2019;
ANAB,12/31/2019,Phase 2b,104.81,ANB020,2019;
ATNM,12/31/2019,Phase 3,0.63,Iomab-B,2H 2019;
AZN,12/31/2019,Phase 3,35.90,Imfinzi + tremelimumab  (POSEIDON),2019;
AZN,12/31/2019,Phase 3,35.90,Imfinzi + tremelimumab (CASPIAN),2019;
AZN,12/31/2019,Phase 3,35.90,Imfinzi + tremelimumab  (DANUBE),2019;
AZN,12/31/2019,Phase 3,35.90,Lynparza - SOLO 3,2019;
AZN,12/31/2019,Phase 3,35.90,Farxiga (Dapa-HF),2019;
AZN,12/31/2019,Phase 3,35.90,Lanabecestat (AZD3293) - AMARANTH,2019;
AZN,12/31/2019,Phase 3,35.90,Durvalumab +/- tremelimumab (DANUBE),2019;
AZN,12/31/2019,Phase 3,35.90,Brilinta (THEMIS),2019;
BCLI,12/31/2019,Phase 3,3.32,NurOwn,Late 2019;
BMRN,12/31/2019,Phase 3,90.82,Vosoritide,2H 2019;
BMY,12/31/2019,Phase 3,63.48,CM-649 – Opdivo+ Yervoy or Chemo,2019;
BMY,12/31/2019,Phase 3,63.48,CM-9LA Opdivo + Yervoy + Chemo,2019;
BMY,12/31/2019,Phase 3,63.48,CM-651 – Opdivo + Yervoy,2019;
CELG,12/31/2019,Phase 3,99.80,REVLIMID - MAGNIFY NHL-010,2019;
CHMA,12/31/2019,Phase 3,1.55,Mycapssa - OPTIMAL,2019;
CNAT,12/31/2019,Phase 2b,5.17,Emricasan,2019;
DCPH,12/31/2019,Phase 3,26.12,DCC-2618 - INVICTUS,2019;
GSK,12/31/2019,Phase 3,37.10,Mepolizumab - SYNAPSE,2019;
IMGN,12/31/2019,Phase 3,9.76,Kadcyla (KAITLIN),2019;
IMMP,12/31/2019,Phase 2b,1.76,Eftilagimod Alpha  - Active Immunotherapy PAClitaxel (AIPAC),2019;
IMRN,12/31/2019,Phase 2,8.05,IMM-124E,2019;
INCY,12/31/2019,Phase 3,85.92,Ruxolitinib - REACH 3,2019;
INCY,12/31/2019,Phase 3,85.92,Ruxolitinib - REACH 2,2019;
JNJ,12/31/2019,Phase 3,137.68,INVOKANA - CREDENCE,2019;
JNJ,12/31/2019,Phase 3,137.68,DARZALEX (Daratumumab),2019;
KALV,12/31/2019,Phase 2,10.76,KVD001,2H 2019;
KPTI,12/31/2019,Phase 2/3,11.66,Selinexor - SEAL,2019;
KPTI,12/31/2019,Phase 3,11.66,Selinexor - BOSTON,2019;
MDCO,12/31/2019,–,32.23,Inclisiran - ORION 11,2H 2019;
MRK,12/31/2019,Phase 3,58.56,MK-8931 (019) - Verubecestat,2019;
NVS,12/31/2019,Phase 3,88.39,QVM149,2019;
NVS,12/31/2019,Phase 3,88.39,QAW039 (fevipiprant),2019;
NVS,12/31/2019,Phase 3,88.39,OMB157 (ofatumumab),2019;
NVS,12/31/2019,Phase 3,88.39,Entresto - PARADISE,2019;
OBSV,12/31/2019,Phase 3,11.00,OBE2109 - PRIMROSE 2,2H 2019;
OBSV,12/31/2019,Phase 3,11.00,OBE2109 - PRIMROSE,2H 2019;
ONTX,12/31/2019,Phase 3,1.36,IV Rigosertib - INSPIRE,2019;
OPHT,12/31/2019,Phase 2a,2.89,Zimura,2H 2019;
OVAS,12/31/2019,Phase 1/2,1.00,OvaPrime,2019;
RETA,12/31/2019,Phase 3,27.80,Bardoxolone methyl - CARDINAL,2H 2019;
RETA,12/31/2019,Phase 2,27.80,Omaveloxolone - MOXIe,2H 2019;
SLGL,12/31/2019,Phase 2,12.41,TWIN,2019;
SLGL,12/31/2019,Phase 2,12.41,VERED,2019;
SLS,12/31/2019,Phase 2,5.93,NeuVax in combination with Herceptin,4Q 2019;
VBIV,12/31/2019,Phase 3,3.89,Sci-B-Vac - PROTECT,2H 2019;
ZYNE,12/31/2019,Phase 2/3,10.92,ZYN002,2019;
ADXS,06/30/2020,Phase 3,2.90,Axalimogene filolisbac - AIM2CERV Trial,2020/21;
MNK,06/30/2020,Phase 3,17.26,Terlipressin,1H 2020;
MNK,06/30/2020,Phase 2,17.26,H.P. Acthar Gel,1H 2020;
MNK,06/30/2020,Phase 3,17.26,UVADEX (methoxsalen) and Therakos,1H 2020;
MNLO,06/30/2020,Phase 3,30.56,Serlopitant,1H 2020;
AGN,12/31/2020,Phase 3,172.51,RELAMORELIN,2020;
AZN,12/31/2020,Phase 3,35.90,Farxiga (Dapa-CKD),2020;
AZN,12/31/2020,Phase 3,35.90,Durvalumab (ADJUVANT),2020;
BLRX,12/31/2020,Phase 3,1.05,BL-8040 GENESIS,2020;
CATB,12/31/2020,Phase 3,1.42,Edasalonexent (CAT-1004),2020;
CELG,12/31/2020,Phase 3,99.80,REVLIMID - MAGNIFY NHL-008,2020;
CHMA,12/31/2020,Phase 3,1.55,Mycapssa - MPOWERED,2020;
CRBP,12/31/2020,Phase 3,7.05,Anabasum (Resunab),2020;
GSK,12/31/2020,Phase 3,37.10,Daprodustat - ASCEND-D,2020;
KZIA,12/31/2020,Phase 2,4.52,GDC-0084,2020;
NVCR,12/31/2020,Phase 3,21.30,Tumor Treating Fields (TTFields) METIS,2020;
ODT,12/31/2020,Phase 3,19.06,Tesetaxel - CONTESSA,2020;
OPHT,12/31/2020,Phase 2b,2.89,Zimura,2020;
PRTA,12/31/2020,Phase 3,39.60,NEOD001 VITAL,2020;
NVCR,12/31/2021,Phase 3,21.30,Tumor Treating Fields (TTFields) LUNAR,2021;
SLGL,12/31/2021,Phase 2,12.41,SIRS-T,2021;
NVS,12/31/2022,Phase 3,88.39,Cosentyx (secukinumab) - SURPASS,2022;
NVS,12/31/2024,Phase 2/3,88.39,CNP 520,2024;
